Global Chemotherapy-Induced Acral Erythema Treatment Market By Product (Analgesics, Anti-inflammatory & Anti-edematous Agents, Antihistaminic, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Oral/Topical Glucocorticoids, Pyridoxine (Vitamin B6), Cold Compression Therapy), By Distribution Channels (Pharmacy & Drugstores, Hospital Pharmacies, Online Drug Stores), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Acral erythema, also known as a Hand-foot Syndrome (HFS) or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness), and desquamation (skin peeling) of the palms, soles, and, on rare occasions, the knees and elbows. Acryl erythema is a type of adverse medication reaction that occurs after several months of therapy with chemotherapeutic medicines, the most prevalent of which are gemcitabine and fluorouracil.

Chemotherapy-induced acryl erythema is a dose-dependent condition that can be treated by stopping chemotherapy or reducing the dosage. Symptomatic treatment with analgesics and antihistaminic medications to minimize pain, and edema is used to treat chemotherapy-induced acryl erythema.

According to the National Center for Biotechnology Information (NCBI), patients treated with capecitabine have a 60% chance of developing HFS.

On September 20, 2020, the Central National Investigations Oncology (CNIO) identified genetic variables linked to HFS in capecitabine chemotherapy.

Detailed Segmentation –

The global chemotherapy-induced acral erythema treatment market is segmented on the basis of – Product Types, Distribution Channels, and Region. Represented below is a detailed segmental description:

Based on Product Types:

• Analgesics
• Anti-inflammatory & Anti-edematous Agents
• Antihistaminic
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Oral/Topical Glucocorticoids
• Pyridoxine (Vitamin B6)
• Cold Compression Therapy
• Other Product Types

Based on Distribution Channels:

• Pharmacy & Drugstores
• Hospital Pharmacies
• Online Drug Stores

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Chemotherapy-Induced Acral Erythema Treatment Market:

The global chemotherapy-induced acral erythema treatment market is being propelled by an increase in the use of chemotherapeutic drugs as a result of the increasing incidence rates of cancer. This factor may help to augment the revenue growth of the global chemotherapy-induced acral erythema treatment market in the years to come.

According to the World Health Organization (WHO) cancer factsheet 2015, the global prevalence of cancer is anticipated to increase by 70% over the next two decades, which may have an positive impact on the economic growth of the global chemotherapy-induced acral erythema treatment market.

Competitive Landscape –

Key players in this market are –

• Taro Pharmaceutical Industries Ltd.
• Oceanside Pharmaceuticals Inc.
• Pfizer
• Novartis AG
• A-S Medication Solutions LLC.
• Preferred Pharmaceuticals Inc.
• Syntex Pharmaceuticals Inc.
• Valeant Canada LP
• Technilab Pharma Inc.
• Allergan Plc.
• others

These key industry players are now focusing on mergers, partnerships, acquisitions, product developments, and collaboration strategies, in order to sustain their respective competitive edge.

For the Chemotherapy-Induced Acral Erythema Treatment Market research study, the following years have been considered to estimate the market size: